Ginkgo Bioworks Holdings (DNA)vsRevolution Medicines Inc (RVMD)
DNA
Ginkgo Bioworks Holdings
$10.23
-0.20%
HEALTHCARE · Cap: $754.88M
RVMD
Revolution Medicines Inc
$176.35
-2.41%
HEALTHCARE · Cap: $41.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 49% more annual revenue ($197.56M vs $132.42M). RVMD leads profitability with a 0.0% profit margin vs -219.6%. DNA earns a higher WallStSmart Score of 28/100 (F).
DNA
Avoid28
out of 100
Grade: F
RVMD
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-27.7%
Fair Value
$7.32
Current Price
$10.23
$2.91 premium
Margin of Safety
+89.8%
Fair Value
$1883.88
Current Price
$176.35
$1707.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Trading at 15.9x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Debt/Equity.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
DNA profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.79 — expect wider price swings.
DNA is growing revenue faster at -48.5% — sustainability is the question.
DNA generates stronger free cash flow (-28M), providing more financial flexibility.
Bottom Line
DNA scores higher overall (28/100 vs 23/100). RVMD offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?